The Ankylosing Spondylitis Disease Activity Score with Erythrocyte Sedimentation Rate (ASDAS-ESR) is a clinical tool used to assess disease activity in patients diagnosed with Ankylosing Spondylitis (AS), a type of chronic inflammatory arthritis that primarily affects the spine. The ASDAS-ESR incorporates patient-reported outcomes and laboratory measures, including the Erythrocyte Sedimentation Rate (ESR), to provide a comprehensive evaluation of disease activity.
The clinical utility of the ASDAS-ESR lies in its ability to monitor disease progression, evaluate the effectiveness of therapeutic interventions, and guide treatment decisions in patients with AS. It is particularly useful in the management of patients with active disease, as it can help to identify those who may benefit from more aggressive treatment strategies.
There are no known specific exclusion criteria for the use of the ASDAS-ESR. However, it should be noted that this score may not be as accurate in patients with conditions that can affect the ESR, such as pregnancy, anemia, or infections. Therefore, clinical judgment should be used when interpreting the ASDAS-ESR in these situations.
Reference
C Lukas, R Landewé, J Sieper et al. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis. 2009 Jan;68(1):18-24.
Open reference URL